462 Progression-free survival 2-progression-free survival 1 in patients with primary advanced/recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
C. Mccourt, G. Ronzino, M. Shahin, Rebecca Kristeleit, L. Willmott, Oleksandr Zub, J. Barlin, L. Gilbert, N. Cloven, Line Bjørge, D. Black, M. Wymenga, Sudarshan Sharma, Michael A Gold, Lisa Landrum, C. Mathews, Grace Antony, S. Stevens, M. Powell, M. Mirza
{"title":"462 Progression-free survival 2-progression-free survival 1 in patients with primary advanced/recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial","authors":"C. Mccourt, G. Ronzino, M. Shahin, Rebecca Kristeleit, L. Willmott, Oleksandr Zub, J. Barlin, L. Gilbert, N. Cloven, Line Bjørge, D. Black, M. Wymenga, Sudarshan Sharma, Michael A Gold, Lisa Landrum, C. Mathews, Grace Antony, S. Stevens, M. Powell, M. Mirza","doi":"10.1136/ijgc-2024-esgo.25","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"62 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
